Imaging resemblance but diagnostic disparity in cervix cancer: a rare case report

Authors

  • Namita Agrawal Department of Gynecology, SDMH, Jaipur, Rajasthan, India
  • Tarun Kumar Jain Department of Nuclear Medicine, MGMCH, Jaipur, Rajasthan, India
  • Abhishek Charan Department of Medical Oncology, MGMCH, Jaipur, Rajasthan, India
  • Sanjay Sharma Department of Surgical Oncology, MGMCH, Jaipur, Rajasthan, India
  • Hemant Malhotra Department of Medical Oncology, MGMCH, Jaipur, Rajasthan, India
  • Nitin Khuteta Department of Surgical Oncology, MGMCH, Jaipur, Rajasthan, India
  • Ajay Yadav Department of Medical Oncology, MGMCH, Jaipur, Rajasthan, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20203345

Keywords:

Cervix carcinoma, F-18 Fluorodeoxyglucose PET-CT, Metastatic carcinoma, Tuberculosis

Abstract

F-18 FDG PET-CT is an establish modality for staging of cervical cancer. The high uptake value in PET with no evidence of necrosis in CECT is generally understood malignant pathology in known cancer patients. A 47 year-old-female with cervix carcinoma underwent staging FDG PET-CT. It showed FDG avid primary lesion in cervix with FDG avid pelvic, retroperitoneal, mediastinal and supraclavicular lymph nodes. USG guided FNA from the supraclavicular lymph node revealed tuberculosis. Now patient scheduled for ATT and chemotherapy.

References

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre LA, Jemal A. Global incidence statistics 2018: GLOBOCAN: estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68:394-424.

Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019;145:129-35.

Liu FY, Lai CH, Yang LY, Wang CC, Lin G, Chang CJ, et al. Utility of (18) F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy: a parallel study of a prospective randomized trial. Eur J Nucl Med Mol Imaging. 2016;43:1812-23.

Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging. 2002;29:797-803.

Kitajima K, Murakami K, Kaji Y, Sakamoto S, Sugimura K. Established, emerging and future applications of FDG-PET/CT in the uterine cancer. Clin Radiol. 2011;66:297‐307.

Hofman MS, Hicks RJ. How we read oncologic FDG PET/CT. Cancer Imaging. 2016;16:35.

Choi J, Kim HJ, Jeong YH, Lee JH, Cho A, Yun M, et al. The role of (18) F-FDG PET/CT in assessing therapy response in cervix cancer after concurrent chemoradiation therapy. Nucl Med Mol Imaging. 2014;48:130-6.

Chung HH, Jo H, Kang WJ, Kim JW, Park NH, Song YS, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol. 2007;104:529-34.

Jain TK. Tuberculosis presenting as cutaneous erythema nodosum on 18F-FDG PET/CT. Clin Nucl Med. 2019;44:e406‐8.

Downloads

Published

2020-07-23

Issue

Section

Case Reports